

## Special Issue

# Regenerative Medicine for Bone and Cartilage

### Message from the Guest Editor

Bone marrow lesions (BMLs) are associated with injuries to the articular cartilage surface; these radiographic findings can represent progression of intra-articular osteochondral lesions, healing following regenerative procedures or precursors to the development of osteoarthritis in the knee. Radiographically, these lesions demonstrate increased sclerosis and/or cystic lesions on X-ray and Cat Scan (CT) images and a bright signal on T2-weighted and a dark signal on T1-weighted magnetic resonance images (MRIs). These imaging findings have been mislabeled as “bone marrow edema” by clinicians but histologically little evidence of inflammation is demonstrated. Pathologically, fibrofatty or fibrovascular (fibrotic) composition, remodeling and trabecular thinning or thickening can be seen. Traumatic contusions with or without ligamentous damage spontaneous insufficiency fractures (SIFs), osteoarthritis, osteonecrosis, and pain syndromes can demonstrate BMLs. Treatment of these conditions varies based on the etiology and clinical findings as a result. This Special Issue will explore the use of regenerative medicine to treat these various conditions.

### Guest Editor

Dr. Deryk Jones

1. Sports Medicine and Cartilage Restoration, Ochsner Sports Medicine Institute, Jefferson, LA 70121, USA
2. Orthopaedics, Medical School, University of Queensland, St. Lucia, QLD 4072, Australia

### Deadline for manuscript submissions

28 February 2026



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/247132](https://mdpi.com/si/247132)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).